發生了什麼事
Enveda Biosciences, a Colorado-based AI drug discovery company, announced it has raised $311 million in a Series E financing round. The funding, led by Catalio Capital Management with participation from 16 other investors including T. Rowe Price and Lux Capital, will be used to advance the company's of AI-identified drug candidates. Enveda uses artificial intelligence to mine plants and microbes for molecular prospects, predicting their structure and function to rank drug potential. Currently, three of these AI-derived candidates are in human testing: ENV-294 for atopic dermatitis and asthma, ENV-308 for maintenance after GLP-1 therapy, and ENV-6949 for inflammatory bowel disease.
Enveda Biosciences announced on Wednesday that it has closed a $311 million Series E financing round. The company, based in Colorado, utilizes artificial intelligence to identify molecules in living organisms such as plants and microbes, predicting their structure and function to rank their potential as drug candidates.
The funding round was led by Catalio Capital Management and included 16 other backers, such as Surveyor Capital, T. Rowe Price, Lux Capital, and a sovereign wealth fund. This brings Enveda's total venture backing to over $841 million, including a previous $150 million Series D round in 2025.
Enveda currently has three AI-derived drug candidates in human testing. ENV-294 is a 'molecular glue' pill for atopic dermatitis and asthma, with Phase 2 trials underway. ENV-308 is designed to mimic the hormone Lac-Phe released during exercise, aiming to help maintain loss after stopping GLP-1 therapies. ENV-6949 targets the TL1A pathway for inflammatory bowel disease.
CEO Viswa Colluru stated that the company is evaluating 17 programs emerging from its AI research. The company's strategy involves putting multiple drugs into the clinic and strategically partnering them at value inflection points to secure both validation and capital to advance other assets.
為什麼這很重要
This significant capital injection validates the commercial viability of AI-driven drug discovery, particularly in identifying novel mechanisms from natural sources. By funding late-stage clinical progression, Enveda aims to demonstrate that AI can accelerate the development of first-in-class therapies for complex conditions like obesity and immune disorders. The round's size, rivaling some biotech IPOs, signals strong investor confidence in the practical application of AI in pharmaceutical R&D, potentially shifting industry standards for how new drug candidates are sourced and validated.
The $311 million raise is substantial for a pre-IPO biotech, rivaling totals secured in larger initial public offerings this year. This suggests that investors are placing high value on AI's ability to de-risk and accelerate early-stage drug discovery.
Enveda's approach of mining natural sources like plants and microbes using AI represents a distinct methodological shift from traditional high-throughput screening or purely computational de novo design. The success of its current clinical candidates will be a key test of this approach's efficacy.
The focus on obesity and immune diseases addresses high-unmet-need areas with significant commercial potential. Specifically, ENV-308's goal of maintaining loss after GLP-1 discontinuation targets a critical gap in current obesity treatment paradigms.
This funding allows Enveda to progress its through the clinic without immediate need for an IPO, providing time to generate more robust clinical data that could further increase its valuation or facilitate strategic partnerships.
互動機制：它實際上是如何運作的
以互動方式探索這項發展背後的基礎技術。
What did neural scaling law research (e.g. Kaplan et al., 2020) observe?
接下來看什麼
Investors and industry observers should monitor the Phase 2 trial results for ENV-294 in eczema and asthma, as well as the upcoming testing of ENV-308 for maintenance post-GLP-1 use. Additionally, watch for strategic partnerships or licensing deals that Enveda may announce to fund further development, as CEO Viswa Colluru has indicated a strategy of partnering assets at value inflection points to secure capital for other programs.
The results of the ongoing Phase 2 trials for ENV-294 in eczema and asthma will be a critical milestone, as they will provide more definitive evidence of the drug's efficacy and safety profile.
The initiation and early results of testing for ENV-308 in maintenance post-GLP-1 use will be closely watched, given the high market interest in sustainable obesity treatments.
Enveda may announce strategic partnerships or licensing agreements for its assets, as indicated by Colluru's strategy of partnering at value inflection points to fund further development.
The company's progress in advancing its other 14 evaluated programs from the AI research phase into clinical trials will indicate the scalability of its AI-driven discovery platform.